HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use LIPITOR safely and effectively. See full prescribing information for LIPITOR.
LIPITOR® (atorvastatin calcium) tablets, for oral use
Initial U.S. Approval: 1996
RECENT MAJOR CHANGES
INDICATIONS AND USAGE
LIPITOR is an HMG-CoA reductase inhibitor indicated as an adjunct therapy to diet to:
Limitations of Use:
LIPITOR has not been studied in Fredrickson Types I and V dyslipidemias (1.3).
DOSAGE AND ADMINISTRATION
DOSAGE FORMS AND STRENGTHS
Tablets: 10, 20, 40, and 80 mg of atorvastatin (3).
WARNINGS AND PRECAUTIONS
The most commonly reported adverse reactions (incidence ≥ 2%) in patients treated with LIPITOR in placebo-controlled trials regardless of causality were: nasopharyngitis, arthralgia, diarrhea, pain in extremity, and urinary tract infection (6.1).
To report SUSPECTED ADVERSE REACTIONS, contact Pfizer at (1-800-438-1985 and www.pfizer.com) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
USE IN SPECIFIC POPULATIONS
See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.